Jump to Content
HOME
BROWSE
SUBJECTS
CLINICAL RESOURCES
DRUG INFORMATION
EDUCATION AND TRAINING
PHARMACY PRACTICE
CAREER DEVELOPMENT
AJHP
DRUG INFORMATION
PROFESSIONAL DEVELOPMENT
Sign in
Sign up
SEARCH
Advanced Search
Help
Sign in
Sign up
HOME
BROWSE
SUBJECTS
CLINICAL RESOURCES
DRUG INFORMATION
EDUCATION AND TRAINING
PHARMACY PRACTICE
CAREER DEVELOPMENT
AJHP
DRUG INFORMATION
PROFESSIONAL DEVELOPMENT
SEARCH
Advanced Search
Help
Search
Table of Contents
Front Matter
Preliminary Material
Introduction
Table 1-1: Cholesterol Concentrations
Table 1-2: Epidemiologic Data for Dyslipidemia
Figure 1-1: Approach to Management of Dyslipidemia
Table 1-3: Comparison of
ATP-III Guidelines, ACC/AHA 2013 Guidelines, and NLA Recommendations
Pathophysiology
Clinical Presentation, Diagnosis, and Disease Classification
Table 1-4: Major Risk Factors for ASCVD
Table 1-5: Criteria for Classification of ASCVD
Table 1-6: National Lipid Association Criteria for ASCVD Risk Assessment, Treatment Goals for Atherogenic Cholesterol, and Levels to Consider Drug Therapy
General Treatment Principles
Table 1-7: Components of Dietary Recommendations
American College of Cardiology/American Heart Association Guidelines
Table 1-8. Statin intensity
National Lipid Association Recommendations
Table 1-9. Risk Indicators (Other than Major ASCVD Risk Factors) that Might Be Considered for Risk Refinement
Table 1-10. Drugs that Can Lead to or Worsen Dyslipidemias
Pharmacotherapy
Statins
Cholesterol Absorption Inhibitors
Bile Acid Sequestrants
Fibric Acid Derivatives
Nicotinic Acid
Omega-3 Fatty Acids
Table 1-11. Relative LDL-Lowering Efficacy of Statin and Statin-Based Therapies
Monitoring
Table 1-12: Lipid Effects of Nonstatin Agents
Table 1-13: Clinical Conditions that Can Worsen Lipid Profiles
Clinical Questions and Controversies
What Impact Do Statins Have on Cognitive Function?
Do Statins Cause or Worsen Type 2 Diabetes?
Are Statins Safe to Use in Patients with Chronic Liver Disease?
What Drug-Drug Interactions Impact Statin Therapy?
Can Fibrates Be Safely Added to a Statin for the Management of Hypertriglyceridemia?
What Is the Best Way to Manage Suspected Statin-Induced Myalgia?
Should Co-enzyme Q10 Be Recommended for the Treatment and/or Prevention of Statin-Associated Muscle Aches?
Which Risk Calculator Is Best?
What Is the Best Strategy to Manage Residual Cardiovascular Risk?
What LDL-C Level Is Too Low?
Should All Patients with an Acute Coronary Event or at High CHD Risk Be Started on High-Dose Statin Therapy?
What Is the Role of CRP in Determining CHD Risk and LDL-C Goals?
Back Matter
Future Treatments
References
Can Fibrates Be Safely Added to a Statin for the Management of Hypertriglyceridemia?
in
Dyslipidemia: Contemporary Evaluation and Management eReport
Editors:
Evan M. Sisson
,
McKenzie Calhoun
, and
Michael A. Crouch
DOI:
https://doi.org/10.37573/9781585284719.028
Restricted access
Email this content
Share Link
Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:
https://publications.ashp.org/abstract/book/9781585284719/ch028.xml
The link was not copied. Your current browser may not support copying via this button.
Link copied successfully
Copy link
Share on facebook
Share on linkedin
Share on twitter
[3.235.145.252]
3.235.145.252
Sign in to annotate
Close
Edit
Character limit
500
/500
Delete
Cancel
Save
@!
Character limit
500
/500
Cancel
Save
View Expanded
View Table
View Full Size